Kisqali (ribociclib) is a brand-name oral tablet that’s prescribed for breast cancer. The cost of the drug with and without insurance can depend on several factors, such as whether Kisqali has a ...

CDK4/6 inhibitors are targeted drugs that can be used for women with a common type of breast cancer: hormone ...

The FDA called out the Instagram post for being misleading and not including facts about the risks associated with Kaléo’s ...

coming in at 90.4% for Kisqali and 87.1% for endocrine therapy, but represented a significant improvement for Novartis’ drug, according to lead investigator Dennis Slamon of UCLA Jonsson ...

As AstraZeneca and Astex's capivasertib gains market presence in breast cancer, could it be the time for AKT inhibitors?

Novartis AG posted impressive Q2 2024 results with strong sales in oncology and heart medication. Read the factors leading to ...

Novartis’ second-quarter earnings, announced Thursday, show strong performance of its blockbuster drugs, prompting the ...

Even among the major drug companies, Novartis has been notably active on the ... The drugmaker also temporarily paused ...

Cancer drug Pluvicto, hit by supply crunch, reported sales of $345 million, up 44%. Sales growth is driven by a strong performance from Entresto, Kesimpta, Cosentyx, Kisqali, Leqvio ...

Sales of multiple sclerosis drug Kesimpta leapt 65 percent to nearly $800 million, the firm said. Breast cancer treatment Kisqali meanwhile saw sales jump more than 50 percent to over $715 million.

The post The 7 Most Undervalued Healthcare Stocks to Buy in July 2024 appeared first on InvestorPlace.

As biopharma companies and the U.S. government near the deadline of their drug price talks under the Inflation Reduction Act (IRA), Novartis CEO said the cost cuts “might be manageable” in the ...